Heritage Investors Management Corp Acquires 718 Shares of Eli Lilly and Company $LLY

Key Points

• Heritage Investors Management Corp increased its Eli Lilly stake by 6.5% in the third quarter, purchasing 718 shares and bringing its holdings to 11,774 shares valued at approximately $13.6 million. Institutional investors collectively own 82.53% of LLY.
• Eli Lilly reported strong quarterly results, with revenue rising 38.6% year over year to $24.4 billion and EPS of $7.48, surpassing analyst expectations. The company also declared a quarterly dividend of $1.73 per share.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $1,404.14, although concerns remain about premium valuation, GLP-1 revenue concentration, and potential pricing pressure.

Heritage Investors Management Corp increased its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 6.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,774 shares of the company's stock after purchasing an additional 718 shares during the period. Heritage Investors Management Corp's holdings in Eli Lilly and Company were worth $13,624,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of LLY. Austin Asset Management Co Inc grew its position in Eli Lilly and Company by 3.3% during the third quarter. Austin Asset Management Co Inc now owns 3,253 shares of the company's stock valued at $3,764,000 after acquiring an additional 103 shares during the period. Verus Financial Partners Inc. increased its stake in Eli Lilly and Company by 4.8% during the third quarter. Verus Financial Partners Inc. now owns 330 shares of the company's stock worth $381,000 after acquiring an additional 15 shares during the last quarter. Columbia Bank increased its stake in Eli Lilly and Company by 2.2% during the third quarter. Columbia Bank now owns 3,674 shares of the company's stock worth $4,251,000 after acquiring an additional 80 shares during the last quarter. Hoey Investments Inc. raised its holdings in shares of Eli Lilly and Company by 23.5% in the 3rd quarter. Hoey Investments Inc. now owns 231 shares of the company's stock worth $267,000 after purchasing an additional 44 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Eli Lilly and Company in the 3rd quarter worth about $366,422,000. Hedge funds and other institutional investors own 82.53% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on LLY. HSBC boosted their price objective on shares of Eli Lilly and Company from $850.00 to $940.00 and gave the stock a "reduce" rating in a research note on Thursday, September 10th. Bank of America reissued a "buy" rating and issued a $1,497.00 target price on shares of Eli Lilly and Company in a research note on Friday. Morgan Stanley lifted their target price on shares of Eli Lilly and Company from $1,430.00 to $1,596.00 and gave the company an "overweight" rating in a report on Friday. Wall Street Zen raised shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Saturday. Finally, The Goldman Sachs Group reaffirmed a "buy" rating and set a $1,413.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, October 20th. One analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $1,404.14.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $1,412.06 on Tuesday. The business's fifty day moving average price is $1,200.81 and its 200 day moving average price is $1,094.25. Eli Lilly and Company has a 12-month low of $850.51 and a 12-month high of $1,449.68. The stock has a market capitalization of $1.33 trillion, a PE ratio of 45.83, a price-to-earnings-growth ratio of 1.73 and a beta of 0.46. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The company reported $7.48 earnings per share for the quarter, beating analysts' consensus estimates of $5.71 by $1.77. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The business had revenue of $24.40 billion during the quarter, compared to the consensus estimate of $22.58 billion. During the same quarter in the prior year, the firm earned $7.02 EPS. The company's revenue for the quarter was up 38.6% compared to the same quarter last year. Equities research analysts forecast that Eli Lilly and Company will post 35.18 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date is Friday, November 13th. Eli Lilly and Company's dividend payout ratio (DPR) is presently 22.46%.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Another strong quarter and higher guidance: Third-quarter revenue rose roughly 39% year over year to $24.4 billion, beating expectations, while adjusted EPS also exceeded estimates. Strong demand for Mounjaro and Zepbound led Lilly to raise its full-year outlook. Eli Lilly Just Delivered Another Blowout Quarter
• Positive Sentiment: Analyst price-target increases: Cantor Fitzgerald raised its target to $1,600 and maintained an “overweight” rating. Other firms, including JPMorgan, also boosted targets, reflecting continued confidence in Lilly’s earnings outlook. Cantor Fitzgerald price target
• Neutral Sentiment: Commercial reorganization: Lilly is combining its U.S. and international commercial operations into one division. The move could improve coordination and execution globally, but its financial effect is not yet clear. Lilly combines commercial divisions
• Negative Sentiment: Pricing and growth concerns: Medicare’s GLP-1 Bridge program and lower realized drug prices may pressure revenue and margins. Analysts also warn that growth could moderate after exceptionally strong results, while one-time revenue benefits may not recur. Lilly’s First Full Medicare Quarter
• Negative Sentiment: High expectations and concentration risk: With about two-thirds of revenue tied to its leading GLP-1 medicines and the shares trading at a premium valuation, investors may be taking profits and demanding evidence that rapid growth can continue. Eli Lilly: Softer Growth Ahead

Insider Activity

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the business's stock in a transaction on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the transaction, the executive vice president owned 11,875 shares in the company, valued at approximately $14,131,250. The trade was a 29.63% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the firm's stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the transaction, the executive vice president directly owned 54,147 shares in the company, valued at $63,628,139.70. This trade represents a 10.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 13,500 shares of company stock valued at $15,958,170. 0.14% of the stock is currently owned by company insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company's portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer's disease.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.